news
Amgen announces positive top-line results from Phase 3 GAUSS-2 trial of Evolocumab (AMG 145) in statin intolerant patients with high cholesterol
23 January 2014 | By Amgen
Study meets co-primary endpoints of LDL cholesterol reduction...
List view / Grid view
Amgen
news
Mass. General, Broad Institute and Amgen will work to discover new drugs for inflammatory bowel disease
15 January 2014 | By Amgen
Collaboration brings unique expertise together focus is to translate IBD gene and biology findings into potential new treatment options for patients...
news
Romosozumab Phase 2 data published In New England Journal Of Medicine show significant increases in bone mineral density at both spine and hip
1 January 2014 | By Amgen
"The results of the study demonstrate significantly increased BMD and stimulation of bone formation with romosozumab treatment..."
news
Amgen announces positive top-line results from phase 3 MENDEL-2 trial of Evolocumab (AMG 145) in patients with high cholesterol
17 December 2013 | By Amgen
Study meets co-primary endpoints of LDL cholesterol reduction...
news
U.S. FDA Approves NEXAVAR® (sorafenib) for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment
22 November 2013 | By Amgen
First and only FDA-approved treatment option for patients with this type of thyroid cancer...
news
Amgen announces evolocumab (AMG 145) results from first 52-week study of a PCSK9 inhibitor to reduce LDL cholesterol
20 November 2013 | By Amgen
Data presented at American Heart Association Scientific sessions 2013 and simultaneously published in circulation...
news
Amgen presents interim overall survival data from Phase 3 study of Talimogene Laherparepvec in patients with metastatic melanoma
18 November 2013 | By Amgen
Differences in survival rates were pronounced in the subset of patients with stage IIIB, IIIC or IV M1a disease...
news
Amgen to highlight new Evolocumab (AMG 145) data at upcoming American Heart Association Scientific Sessions 2013
14 November 2013 | By Amgen
First long-term data of a PCSK9 Inhibitor to be featured in clinical science: special reports session...
news
Amgen Foundation commits $2.5 Million in new grants to engage 50,000 students each year in the thrill of scientific inquiry
7 November 2013 | By Amgen
Innovative program - Amgen Biotech Experience - brings real-world biotechnology lab experience to students...
article
Raman spectroscopy In-Depth Focus 2013
In this Raman spectroscopy In-Depth Focus: Raw material identification using dual laser handheld Raman spectroscopy; Raman spectroscopy in support of biotherapeutic production: applications in protein formulation and purification; Raman Spectroscopy Roundtable...
news
Amgen promotes two senior executives: names Brian McNamee executive vice president and Stuart Tross senior vice president
24 October 2013 | By Amgen
McNamee will be responsible for leading a series of multi-year initiatives aimed at delivering growth and increasing productivity...
news
Amgen announces appointment of Greg C. Garland to Board of Directors
16 October 2013 | By Amgen
Mr. Garland will serve on the Governance and Nominating Committee and the Audit Committee of the Board...
news
Amgen presents nearly two dozen abstracts from Romosozumab and Prolia® (Denosumab) at ASBMR
4 October 2013 | By Amgen
Prolia open-label extension trial showed continued increases in bone mineral density and low fracture incidence for up to eight years...
news
Amgen and AstraZeneca highlight data to be presented at 22nd congress of the European Academy of Dermatology and Venereology
3 October 2013 | By Amgen
"The Phase 2 data demonstrate that the primary and secondary end points were met..."
news
Amgen successfully completes Onyx pharmaceuticals tender offer
1 October 2013 | By Amgen
"Amgen's acquisition of Onyx fits perfectly with our commitment to advancing medicines for cancer patients around the world..."
